药械协同步入新时代。近两年,国内创新药企业靠着BD在营收上增加了不少数字,但多数产品管线离商业化兑现还有相当长的距离。在创新药这个以10年为周期的行业中,药企想跑出成绩,必须寻找新的增长曲线,而医疗器械,正成为众多药企选中的加速器。药企跨界做器械并非什么新鲜事,但过去很多跨界多是一些技术含量较低的领域,谈不上什么战略层面的目标,更多只是短期利益的考量。随着创新药一哥恒瑞的入局,可以看到药企对于药械...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.